Listed

Amphastar Pharmaceuticals, Inc.: Form 10-Q for the period ended Jun 30, 2014

Filed with the SEC on Aug 13, 2014 and accepted by EDGAR at Aug 13, 2014, 16:17 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2014-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2014-04-01 to 2014-06-30$49.0mus-gaap:SalesRevenueNet
Revenue6 months2014-01-01 to 2014-06-30$94.9mus-gaap:SalesRevenueNet
Cost of revenue3 months2014-04-01 to 2014-06-30$34.0mus-gaap:CostOfRevenue
Cost of revenue6 months2014-01-01 to 2014-06-30$67.4mus-gaap:CostOfRevenue
Gross profit3 months2014-04-01 to 2014-06-30$15.0mus-gaap:GrossProfit
Gross profit6 months2014-01-01 to 2014-06-30$27.5mus-gaap:GrossProfit
Research and development3 months2014-04-01 to 2014-06-30$6.0mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2014-01-01 to 2014-06-30$12.2mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2014-04-01 to 2014-06-30−$1.2mus-gaap:OperatingIncomeLoss
Operating income6 months2014-01-01 to 2014-06-30−$3.1mus-gaap:OperatingIncomeLoss
Interest expense3 months2014-04-01 to 2014-06-30$476.0kus-gaap:InterestExpense
Interest expense6 months2014-01-01 to 2014-06-30$655.0kus-gaap:InterestExpense
Income tax3 months2014-04-01 to 2014-06-30−$696.0kus-gaap:IncomeTaxExpenseBenefit
Income tax6 months2014-01-01 to 2014-06-30−$1.5mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2014-04-01 to 2014-06-30−$1.2mus-gaap:NetIncomeLoss
Net income6 months2014-01-01 to 2014-06-30−$2.8mus-gaap:NetIncomeLoss
Diluted EPS3 months2014-04-01 to 2014-06-30−$0.03us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2014-01-01 to 2014-06-30−$0.07us-gaap:EarningsPerShareDiluted
Basic EPS3 months2014-04-01 to 2014-06-30−$0.03us-gaap:EarningsPerShareBasic
Basic EPS6 months2014-01-01 to 2014-06-30−$0.07us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2014-04-01 to 2014-06-3039,767,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2014-01-01 to 2014-06-3039,268,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2014-01-01 to 2014-06-30−$4.9mus-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
Capital expenditure6 months2014-01-01 to 2014-06-30$7.1mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2014-06-30$64.1mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2014-06-30$214.2mus-gaap:AssetsCurrent
Total assetsAt period end2014-06-30$397.3mus-gaap:Assets
Current liabilitiesAt period end2014-06-30$56.3mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2014-06-30$109.5mus-gaap:Liabilities
Shareholders' equityAt period end2014-06-30$287.7mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001171843-14-003951. Last ingested by Listed: Nov 6, 2026, 17:01 ET. Listed shows no prices and gives no investment advice.